Predicting Efficacy of Oxaliplatin in Colorectal Cancer
Author Information
Author(s): Bensmaïne M A, Marty M, Gramont A de, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E
Hypothesis
What factors predict the efficacy of oxaliplatin in patients with 5-FU-resistant advanced colorectal cancer?
Conclusion
The study found that certain baseline factors can predict the effectiveness of oxaliplatin treatment in patients with advanced colorectal cancer who are resistant to 5-FU.
Supporting Evidence
- The overall response rate (ORR) was 16%.
- The median time to progression (TTP) was 4.2 months.
- The median overall survival (OS) was 9.6 months.
- Poor performance status and a large number of prior chemotherapy regimens were associated with lower ORR.
- Male sex and a higher number of organs involved were linked to shorter TTP.
- Poor performance status and elevated alkaline phosphatase levels correlated with shorter OS.
Takeaway
Doctors can use specific patient information to better understand how well oxaliplatin will work for people with a certain type of cancer.
Methodology
Statistical analysis of patient data from compassionate-use programs using logistic and Cox proportional hazards analyses.
Participant Demographics
Patients were mostly with performance status ≤ 2 and had received ≥ 2 prior lines of chemotherapy.
Statistical Information
Confidence Interval
95% CI: 13–20 for ORR; 95% CI: 3.4–4.6 for TTP; 95% CI: 8.6–10.6 for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website